CLGN
CollPlant Biotechnologies Ltd.
Set alert
- YTD
- -70.46%
- 1 year
- -81.12%
- Open
- 4.20
- Prev close
- 4.40
- Mkt cap
- 11.91M
- Vol
- 44.25K
- Avg vol
- 365.75K
- EPS
- -9.33
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.10
- High
- 4.60
- Forward P/E
- -8.82
- Beta
- 0.48
- Short ratio
- 0.70
- Inst. own
- 12.23%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 20, 2024
- 50-d avg
- 4.04
- 200-d avg
- 4.90
- 1y target
- 12.50
Key statistics
- Market cap
- 39.40M
- Enterprise value
- 33.32M
- Trailing P/E
- 0.00
- Forward P/E
- -8.82
- PEG ratio
- 0.00
- Price / sales
- 57.19
- Price / book
- 1.39
- EPS (TTM)
- -1.53
- Beta
- 0.48
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 689.00K
- Revenue growth
- -97.60%
- Free cash flow
- 2.13M
- Total cash
- 18.92M
- Total debt
- 3.38M
- Return on equity
- -61.55%
- Shares outstanding
- 11.45M
- Short % of float
- 0.15%
- 50-day average
- 4.04
- 200-day average
- 4.90
Analyst view
Consensus: none
- Target (low)
- 11.00
- Target (mean)
- 12.50
- Target (high)
- 14.00
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 20, 2024
Expected Aug 20, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 27, 2024 | Sep 1, 2024 | -0.37 | -0.38 | -0.01 | -2.70% |
| Aug 20, 2024 | Jun 1, 2024 | -0.35 | -0.37 | -0.02 | -5.71% |
| Aug 20, 2024 | Jun 1, 2024 | -0.35 | — | — | — |
| May 29, 2024 | Mar 1, 2024 | -0.35 | -0.37 | -0.02 | -5.71% |
| May 29, 2024 | Mar 1, 2024 | -0.35 | — | — | — |
| Apr 4, 2024 | Dec 1, 2023 | 0.00 | -0.42 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 29, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 27, 2024 | D. Boral Capital | main | Buy | Buy |
| Aug 21, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 20, 2024 | EF Hutton | main | Buy | Buy |
| Aug 5, 2024 | EF Hutton | init | — | Buy |
| May 30, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About CollPlant Biotechnologies Ltd.
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- collplant.com
News
- Reported Earlier: CollPlant Subsidiary LightSolver Signs Multi-Year Israel Defense Ministry Agreement For Photonic Computing, Secures Initial 12-Month Order In Defense Market With Estimated $5B Annual TAM, 15% CAGR
- LightSolver Secures Paid Collaboration with the Israel Ministry of Defense for the Development of Photonic Computing Technology
- 12 Health Care Stocks Moving In Monday's Intraday Session
- CollPlant Biotechnologies Announces Private Placement Of 989,301 Shares And Warrants To Purchase Up To 1,483,952 Shares At $3.74/Unit
- COLLPLANT ANNOUNCES A $3.7 MILLION PRIVATE PLACEMENT
- CollPlant Biotechnologies Unit LightSolver Files U.S. Provisional Patent Application For Expansion Of Its All-Optical, Laser-Based Computing Platform
- LightSolver Files U.S. Provisional Patent Application Expanding its Photonic Computing Platform to Advanced Scientific and Engineering Simulations
- Critical Contrast: CollPlant Biotechnologies (NASDAQ:CLGN) & CareDx (NASDAQ:CDNA)
- CollPlant Biotechnologies Q2 Adj. EPS $(1.69) Misses $(0.24) Estimate, Sales $108.000K Miss $1.466M Estimate
- COLLPLANT REPORTS 2026 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Your note
Sign in to keep a note on CLGN — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Villere St. Denis J. & Co. LLC | 4.33% | 484,867 | 1.67M | Sep 29, 2024 |
| Pinnacle Associates, Ltd. | 4.18% | 468,109 | 1.61M | Sep 29, 2024 |
| Brown Advisory Inc. | 1.07% | 119,465 | 410.96K | Sep 29, 2024 |
| AMH Equity Ltd. | 0.89% | 99,205 | 341.26K | Sep 29, 2024 |
| Benjamin Edwards, Inc. | 0.21% | 23,810 | 81.91K | Sep 29, 2024 |
| Pathstone Holdings, LLC | 0.15% | 17,000 | 58.48K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.05% | 5,925 | 20.38K | Oct 30, 2024 |